NCT06528769View on ClinicalTrials.gov

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
LeiomyosarcomaSarcoma
Interventions
DRUG

all-trans retinoic acid

Given orally

DRUG

Cemiplimab

Given intravenously (IV)

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic resonance imaging

Undergo MRI

PROCEDURE

Biospecimen Collection

Undergo blood and urine sample collection

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Gabriel Tinoco

OTHER